How long can pralsetinib be maintained?

In general, the duration of pralsetinib treatment varies depending on the disease being treated and individual differences in drug resistance. For RET fusion-positive non-small cell lung cancer, the maintenance period is approximately 1–2 years, while for medullary thyroid cancer, it may be slightly longer. If there are any concerns, it is recommended to seek medical advice promptly. A detailed analysis is as follows:

When used to treat RET fusion-positive non-small cell lung cancer, most patients maintain stable disease for about 1–2 years after following standardized medication. During this period, tumor growth is suppressed and symptoms are controlled. Some patients who are highly sensitive to the drug may experience a longer response duration, whereas others may develop drug resistance earlier, shortening the treatment efficacy and requiring timely adjustment of the treatment plan.

When used for treating RET-mutant medullary thyroid cancer, the drug's effectiveness may last relatively longer, with some patients maintaining response for over 2 years. After treatment, tumor-related markers (such as calcitonin and carcinoembryonic antigen) gradually decrease, leading to more stable disease control. However, regular monitoring is still necessary to detect potential late-onset drug resistance and prevent disease progression.

During pralsetinib treatment, patients must strictly follow medical instructions—do not discontinue or reduce the dose without consultation. Regular imaging studies and tumor marker tests should be performed to evaluate disease status. If signs of drug resistance or new discomfort arise, prompt medical attention is required to adjust the treatment strategy and ensure therapeutic effectiveness.